Bluebird Bio (BLUE) will present data from the ongoing Phase 2/3 Starbeam Study (ALD-102) for the treatment of cerebral adrenoleukodystrophy (CALD) at the American Academy of Neurology (AAN) 2016 Annual Meeting
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Slingshot Insights Explained
Don’t see a project related to the catalyst you care about?